Liposomal formulation of irinotecan
US7122553B2 · kind B2 · utility
3Cited by
115References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 19, 2003 |
| Grant date | Oct 17, 2006 |
| Priority date | — |
| Expiry date | Nov 19, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/685
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is for novel compositions and methods for treating cancer, particularly, for treating cancer in mammals and more particularly in humans. The therapeutic compositions of the present invention include liposome entrapped irinotecan in which the liposome can contain any of a variety of neutral or charged liposome-forming compounds and cardiolipin. The liposomes of the present invention can be either multilamellar vesicles and unilamellar vesicles, as desired.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.